Vitiligo is an autoimmune skin pigmented disorder mediated by autoreactive IFN-γ- producing CD8+ T cells that attack melanocytes, leading to loss of skin pigmentation (Figure 7). The appearance of vitiligo in melanoma patients treated with anti-PD-1 immune checkpoint inhibitors is well known as an immune-related adverse event. This evidence concerns the gene IFNG and vitiligo.